In vitro <\/em>activity for ZERBAXA\u00ae (ceftolozane and tazobactam)<\/strong><\/h1><\/div>\n\n\n\n\n<\/div>\n\n\n\nZERBAXA demonstrated potent in vitro activity against P. aeruginosa<\/em>1<\/sup><\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n\n\n\n- The clinical significance of in vitro data is unknown<\/strong>.<\/li>\n\n\n\n
- Limitations of the SMART data include: lack of clinical information to confirm nosocomial versus community-acquired isolates, relatively small number of isolates tested each year (n=250 per site), small number of sites, and change of sites participating in SMART study over time.1<\/sup><\/li>\n\n\n\n
- Culture and susceptibility information and local epidemiology should be considered in modifying antibacterial therapy.<\/li>\n\n\n\n
- ZERBAXA is not active against bacteria that produce serine carbapenemases (K. pneumoniae<\/em> carbapenemase [KPC]), and metallo-beta-lactamases.<\/li>\n<\/ul>\n<\/div>\n\n\n\n<\/div>\n\n\n\n
Susceptibility rates for select ICU respiratory tract isolates in U.S. surveillance data (2023-2024)1,a<\/sup><\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n<\/div>\n\n\n\n\n\n\n![\"Susceptibility](\"https:\/\/www.merckconnect.com\/zerbaxa\/wp-content\/uploads\/sites\/130\/2025\/10\/CAT_4_Isolates_BarChart_23-4_dk_RGB.svg\")
<\/p><\/figcaption><\/figure><\/div>\n<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\na<\/sup>Isolates were collected as part of the Study for Monitoring Antimicrobial Resistance Trends (SMART 2023-2024).1<\/sup><\/p><\/div><\/div>\n\n\n\n<\/div>\n\n\n\nStudy design1<\/sup><\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\nThe Study for Monitoring Antimicrobial Resistance Trends (SMART) represents the commitment of Merck to monitor the in vitro susceptibility of clinical bacterial Gram-negative isolates to antimicrobials in intra-abdominal (since 2002), urinary tract (since 2009), respiratory tract (since 2015), and bloodstream infections (since 2019). SMART was initiated in 2002 and is a global study. This report specifically focuses on isolates from respiratory tract infections (RTIs), collected from 2023 and 2024.<\/p>\n\n\n\n
<\/div>\n\n\n\nMinimum inhibitory concentration (MIC) values for ceftolozane\/tazobactam and comparator agents were determined using the broth microdilution methodology recommended by the Clinical and Laboratory Standards Institute (CLSI) that was current in the year the data was collected. The following breakpoints were used to test for the susceptibility of P. aeruginosa<\/em> for ZERBAXA (MICs [mcg\/mL]): \u22644\/4 (susceptible).<\/p>\n\n\n\n<\/div>\n\n\n\n\n- Back to top<\/a><\/em><\/li>
- Clinical efficacy against HABP\/VABP<\/a><\/em><\/li>
- Clinical efficacy against cUTI<\/a><\/em><\/li>
- Clinical efficacy against cIAIs<\/a><\/em><\/li><\/ul><\/div>\n\n\n\n<\/div>\n\n\n\n
ZERBAXA: 9 years of P.aeruginosa<\/em> susceptibility data<\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n\n\n- The clinical significance of in vitro data is unknown.<\/strong><\/li>\n\n\n\n
- Limitations of the SMART data include: lack of clinical information to confirm nosocomial versus community-acquired isolates, relatively small number of isolates tested each year (n=250 per site), small number of sites, and change of sites participating in SMART study over time.2<\/sup><\/li>\n\n\n\n
- Contributing centers collected consecutive Gram-negative bacilli from hospitalized patients with intra-abdominal, urinary, respiratory tract, or bloodstream infections.2<\/sup><\/li>\n\n\n\n
- Culture and susceptibility information and local epidemiology should be considered in modifying antibacterial therapy.<\/li>\n\n\n\n
- ZERBAXA is not active against bacteria that produce serine carbapenemases (K. pneumoniae<\/em> carbapenemase [KPC]), and metallo-beta-lactamases.<\/li>\n<\/ul>\n<\/div>\n\n\n\n<\/div>\n\n\n\n
Susceptibility rates for select isolates in US surveillance data (2016-2024)2,a<\/sup><\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n![\"Susceptibility](\"https:\/\/www.merckconnect.com\/zerbaxa\/wp-content\/uploads\/sites\/130\/2026\/03\/CAT_ZER_PsA_9yrs_chart_MC_RGB-1.svg\")
<\/figure><\/div>\n\n\n\na<\/sup>Isolates were collected as part of the Study for Monitoring Antimicrobial Resistance Trends (SMART 2016-2024).2<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\nStudy design2<\/sup><\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\nThe Study for Monitoring Antimicrobial Resistance Trends (SMART) was initiated by Merck in 2002 and represents the commitment of Merck to monitor the in vitro susceptibility of clinical aerobic and facultative Gram-negative bacterial isolates from intra-abdominal infections (IAIs) to selected antimicrobials internationally, enabling longitudinal analyses to determine if susceptibility patterns changed over time. Collection of isolates from urinary tract infections (UTIs), lower respiratory tract infections (RTIs), and bloodstream infections (BSIs) started in 2009, 2015, and 2019, respectively. Each participating site collected up to the indicated number of consecutive clinically relevant isolates of Gram-negative bacilli: 100 from patients with RTIs, 50 from IAIs, 50 from UTIs, and 50 from BSIs. <\/p>\n\n\n\n
<\/div>\n\n\n\nThe above collection of isolates represents the United States surveillance data of P. aeruginosa<\/em> susceptibility to ceftolozane\/tazobactam between 2016 and 2024. Minimum inhibitory concentration (MIC) was interpreted using current Clinical & Laboratory Standards Institute (CLSI) guidelines available in the United States. The following breakpoints were used to test for the susceptibility of P. aeruginosa<\/em> for ZERBAXA (MICs [mcg\/mL]): \u22644\/4 (susceptible).<\/p>\n\n\n\n<\/div>\n\n\n\n- Back to top<\/a><\/em><\/li>
- Clinical efficacy against HABP\/VABP<\/a><\/em><\/li>
- Clinical efficacy against cUTI<\/a><\/em><\/li>
- Clinical efficacy against cIAIs<\/a><\/em><\/li><\/ul><\/div>\n\n\n\n<\/div>\n\n\n\n
References<\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n- Data available on request from the Merck National Service Center via email at daprequests@merck.com. Please specify information package US-ZER-02083<\/span>.<\/li>
- Data available on request from the Merck National Service Center via email at daprequests@merck.com. Please specify information package US-ZER-02140<\/span>.<\/li><\/ol><\/div>\n\n\n\n<\/div>\n","protected":false},"excerpt":{"rendered":"
aIsolates were collected as part of the Study for Monitoring Antimicrobial Resistance Trends (SMART 2023-2024).1 The Study for Monitoring Antimicrobial Resistance Trends…<\/p>\n","protected":false},"author":750,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_trash_the_other_posts":false,"editor_notices":[],"footnotes":""},"ga4_page_audience":[],"ga4_page_birn_id":[],"ga4_page_branding":[267],"ga4_page_businessunit":[],"ga4_page_campaign":[],"ga4_page_content_purpose":[283],"ga4_page_customer_journey_stage":[334],"ga4_page_customer_specialty":[358],"ga4_page_experience":[],"ga4_page_indication":[],"ga4_page_material_intent":[522],"ga4_page_product":[706],"ga4_page_region":[749],"ga4_page_therapeuticarea":[],"user_role":[],"mhh-area-of-interest":[],"access":[],"user_status":[],"class_list":["post-106","page","type-page","status-publish"],"yoast_head":"\n
In Vitro Activity for ZERBAXA\u00ae (ceftolozane and tazobactam)<\/title>\n<meta name=\"description\" content=\"Review data for the in vitro activity of ZERBAXA\u00ae (ceftolozane and tazobactam).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"In Vitro Activity for ZERBAXA\u00ae (ceftolozane and tazobactam)\" \/>\n<meta property=\"og:description\" content=\"Review data for the in vitro activity of ZERBAXA\u00ae (ceftolozane and tazobactam).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/\" \/>\n<meta property=\"og:site_name\" content=\"zerbaxa\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-09T12:20:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.merckconnect.com\/zerbaxa\/wp-content\/uploads\/sites\/130\/2025\/10\/CAT_4_Isolates_BarChart_23-4_dk_RGB.svg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"In Vitro Activity for ZERBAXA\u00ae (ceftolozane and tazobactam)","description":"Review data for the in vitro activity of ZERBAXA\u00ae (ceftolozane and tazobactam).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/","og_locale":"en_US","og_type":"article","og_title":"In Vitro Activity for ZERBAXA\u00ae (ceftolozane and tazobactam)","og_description":"Review data for the in vitro activity of ZERBAXA\u00ae (ceftolozane and tazobactam).","og_url":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/","og_site_name":"zerbaxa","article_modified_time":"2026-04-09T12:20:50+00:00","og_image":[{"url":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-content\/uploads\/sites\/130\/2025\/10\/CAT_4_Isolates_BarChart_23-4_dk_RGB.svg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/","url":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/","name":"In Vitro Activity for ZERBAXA\u00ae (ceftolozane and tazobactam)","isPartOf":{"@id":"https:\/\/www.merckconnect.com\/zerbaxa\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/#primaryimage"},"image":{"@id":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/#primaryimage"},"thumbnailUrl":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-content\/uploads\/sites\/130\/2025\/10\/CAT_4_Isolates_BarChart_23-4_dk_RGB.svg","datePublished":"2023-08-29T13:14:44+00:00","dateModified":"2026-04-09T12:20:50+00:00","description":"Review data for the in vitro activity of ZERBAXA\u00ae (ceftolozane and tazobactam).","breadcrumb":{"@id":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.merckconnect.com\/zerbaxa\/"},{"@type":"ListItem","position":2,"name":"Nonclinical data"}]},{"@type":"WebSite","@id":"https:\/\/www.merckconnect.com\/zerbaxa\/#website","url":"https:\/\/www.merckconnect.com\/zerbaxa\/","name":"zerbaxa","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.merckconnect.com\/zerbaxa\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/pages\/106","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/users\/750"}],"replies":[{"embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/comments?post=106"}],"version-history":[{"count":64,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/pages\/106\/revisions"}],"predecessor-version":[{"id":2605,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/pages\/106\/revisions\/2605"}],"wp:attachment":[{"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/media?parent=106"}],"wp:term":[{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_audience?post=106"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_birn_id?post=106"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_branding?post=106"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_businessunit?post=106"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_campaign?post=106"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=106"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=106"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=106"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_experience?post=106"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_indication?post=106"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_material_intent?post=106"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_product?post=106"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_region?post=106"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=106"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/user_role?post=106"},{"taxonomy":"mhh-area-of-interest","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/mhh-area-of-interest?post=106"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/access?post=106"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/user_status?post=106"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
ZERBAXA demonstrated potent in vitro activity against P. aeruginosa<\/em>1<\/sup><\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n\n\n\n- The clinical significance of in vitro data is unknown<\/strong>.<\/li>\n\n\n\n
- Limitations of the SMART data include: lack of clinical information to confirm nosocomial versus community-acquired isolates, relatively small number of isolates tested each year (n=250 per site), small number of sites, and change of sites participating in SMART study over time.1<\/sup><\/li>\n\n\n\n
- Culture and susceptibility information and local epidemiology should be considered in modifying antibacterial therapy.<\/li>\n\n\n\n
- ZERBAXA is not active against bacteria that produce serine carbapenemases (K. pneumoniae<\/em> carbapenemase [KPC]), and metallo-beta-lactamases.<\/li>\n<\/ul>\n<\/div>\n\n\n\n<\/div>\n\n\n\n
Susceptibility rates for select ICU respiratory tract isolates in U.S. surveillance data (2023-2024)1,a<\/sup><\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n<\/div>\n\n\n\n\n\n\n<\/p><\/figcaption><\/figure><\/div>\n<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\na<\/sup>Isolates were collected as part of the Study for Monitoring Antimicrobial Resistance Trends (SMART 2023-2024).1<\/sup><\/p><\/div><\/div>\n\n\n\n<\/div>\n\n\n\nStudy design1<\/sup><\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\nThe Study for Monitoring Antimicrobial Resistance Trends (SMART) represents the commitment of Merck to monitor the in vitro susceptibility of clinical bacterial Gram-negative isolates to antimicrobials in intra-abdominal (since 2002), urinary tract (since 2009), respiratory tract (since 2015), and bloodstream infections (since 2019). SMART was initiated in 2002 and is a global study. This report specifically focuses on isolates from respiratory tract infections (RTIs), collected from 2023 and 2024.<\/p>\n\n\n\n
<\/div>\n\n\n\nMinimum inhibitory concentration (MIC) values for ceftolozane\/tazobactam and comparator agents were determined using the broth microdilution methodology recommended by the Clinical and Laboratory Standards Institute (CLSI) that was current in the year the data was collected. The following breakpoints were used to test for the susceptibility of P. aeruginosa<\/em> for ZERBAXA (MICs [mcg\/mL]): \u22644\/4 (susceptible).<\/p>\n\n\n\n<\/div>\n\n\n\n\n- Back to top<\/a><\/em><\/li>
- Clinical efficacy against HABP\/VABP<\/a><\/em><\/li>
- Clinical efficacy against cUTI<\/a><\/em><\/li>
- Clinical efficacy against cIAIs<\/a><\/em><\/li><\/ul><\/div>\n\n\n\n<\/div>\n\n\n\n
ZERBAXA: 9 years of P.aeruginosa<\/em> susceptibility data<\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n\n\n- The clinical significance of in vitro data is unknown.<\/strong><\/li>\n\n\n\n
- Limitations of the SMART data include: lack of clinical information to confirm nosocomial versus community-acquired isolates, relatively small number of isolates tested each year (n=250 per site), small number of sites, and change of sites participating in SMART study over time.2<\/sup><\/li>\n\n\n\n
- Contributing centers collected consecutive Gram-negative bacilli from hospitalized patients with intra-abdominal, urinary, respiratory tract, or bloodstream infections.2<\/sup><\/li>\n\n\n\n
- Culture and susceptibility information and local epidemiology should be considered in modifying antibacterial therapy.<\/li>\n\n\n\n
- ZERBAXA is not active against bacteria that produce serine carbapenemases (K. pneumoniae<\/em> carbapenemase [KPC]), and metallo-beta-lactamases.<\/li>\n<\/ul>\n<\/div>\n\n\n\n<\/div>\n\n\n\n
Susceptibility rates for select isolates in US surveillance data (2016-2024)2,a<\/sup><\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n<\/figure><\/div>\n\n\n\na<\/sup>Isolates were collected as part of the Study for Monitoring Antimicrobial Resistance Trends (SMART 2016-2024).2<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\nStudy design2<\/sup><\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\nThe Study for Monitoring Antimicrobial Resistance Trends (SMART) was initiated by Merck in 2002 and represents the commitment of Merck to monitor the in vitro susceptibility of clinical aerobic and facultative Gram-negative bacterial isolates from intra-abdominal infections (IAIs) to selected antimicrobials internationally, enabling longitudinal analyses to determine if susceptibility patterns changed over time. Collection of isolates from urinary tract infections (UTIs), lower respiratory tract infections (RTIs), and bloodstream infections (BSIs) started in 2009, 2015, and 2019, respectively. Each participating site collected up to the indicated number of consecutive clinically relevant isolates of Gram-negative bacilli: 100 from patients with RTIs, 50 from IAIs, 50 from UTIs, and 50 from BSIs. <\/p>\n\n\n\n
<\/div>\n\n\n\nThe above collection of isolates represents the United States surveillance data of P. aeruginosa<\/em> susceptibility to ceftolozane\/tazobactam between 2016 and 2024. Minimum inhibitory concentration (MIC) was interpreted using current Clinical & Laboratory Standards Institute (CLSI) guidelines available in the United States. The following breakpoints were used to test for the susceptibility of P. aeruginosa<\/em> for ZERBAXA (MICs [mcg\/mL]): \u22644\/4 (susceptible).<\/p>\n\n\n\n<\/div>\n\n\n\n- Back to top<\/a><\/em><\/li>
- Clinical efficacy against HABP\/VABP<\/a><\/em><\/li>
- Clinical efficacy against cUTI<\/a><\/em><\/li>
- Clinical efficacy against cIAIs<\/a><\/em><\/li><\/ul><\/div>\n\n\n\n<\/div>\n\n\n\n
References<\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n- Data available on request from the Merck National Service Center via email at daprequests@merck.com. Please specify information package US-ZER-02083<\/span>.<\/li>
- Data available on request from the Merck National Service Center via email at daprequests@merck.com. Please specify information package US-ZER-02140<\/span>.<\/li><\/ol><\/div>\n\n\n\n<\/div>\n","protected":false},"excerpt":{"rendered":"
aIsolates were collected as part of the Study for Monitoring Antimicrobial Resistance Trends (SMART 2023-2024).1 The Study for Monitoring Antimicrobial Resistance Trends…<\/p>\n","protected":false},"author":750,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_trash_the_other_posts":false,"editor_notices":[],"footnotes":""},"ga4_page_audience":[],"ga4_page_birn_id":[],"ga4_page_branding":[267],"ga4_page_businessunit":[],"ga4_page_campaign":[],"ga4_page_content_purpose":[283],"ga4_page_customer_journey_stage":[334],"ga4_page_customer_specialty":[358],"ga4_page_experience":[],"ga4_page_indication":[],"ga4_page_material_intent":[522],"ga4_page_product":[706],"ga4_page_region":[749],"ga4_page_therapeuticarea":[],"user_role":[],"mhh-area-of-interest":[],"access":[],"user_status":[],"class_list":["post-106","page","type-page","status-publish"],"yoast_head":"\n
In Vitro Activity for ZERBAXA\u00ae (ceftolozane and tazobactam)<\/title>\n<meta name=\"description\" content=\"Review data for the in vitro activity of ZERBAXA\u00ae (ceftolozane and tazobactam).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"In Vitro Activity for ZERBAXA\u00ae (ceftolozane and tazobactam)\" \/>\n<meta property=\"og:description\" content=\"Review data for the in vitro activity of ZERBAXA\u00ae (ceftolozane and tazobactam).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/\" \/>\n<meta property=\"og:site_name\" content=\"zerbaxa\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-09T12:20:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.merckconnect.com\/zerbaxa\/wp-content\/uploads\/sites\/130\/2025\/10\/CAT_4_Isolates_BarChart_23-4_dk_RGB.svg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"In Vitro Activity for ZERBAXA\u00ae (ceftolozane and tazobactam)","description":"Review data for the in vitro activity of ZERBAXA\u00ae (ceftolozane and tazobactam).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/","og_locale":"en_US","og_type":"article","og_title":"In Vitro Activity for ZERBAXA\u00ae (ceftolozane and tazobactam)","og_description":"Review data for the in vitro activity of ZERBAXA\u00ae (ceftolozane and tazobactam).","og_url":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/","og_site_name":"zerbaxa","article_modified_time":"2026-04-09T12:20:50+00:00","og_image":[{"url":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-content\/uploads\/sites\/130\/2025\/10\/CAT_4_Isolates_BarChart_23-4_dk_RGB.svg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/","url":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/","name":"In Vitro Activity for ZERBAXA\u00ae (ceftolozane and tazobactam)","isPartOf":{"@id":"https:\/\/www.merckconnect.com\/zerbaxa\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/#primaryimage"},"image":{"@id":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/#primaryimage"},"thumbnailUrl":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-content\/uploads\/sites\/130\/2025\/10\/CAT_4_Isolates_BarChart_23-4_dk_RGB.svg","datePublished":"2023-08-29T13:14:44+00:00","dateModified":"2026-04-09T12:20:50+00:00","description":"Review data for the in vitro activity of ZERBAXA\u00ae (ceftolozane and tazobactam).","breadcrumb":{"@id":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.merckconnect.com\/zerbaxa\/"},{"@type":"ListItem","position":2,"name":"Nonclinical data"}]},{"@type":"WebSite","@id":"https:\/\/www.merckconnect.com\/zerbaxa\/#website","url":"https:\/\/www.merckconnect.com\/zerbaxa\/","name":"zerbaxa","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.merckconnect.com\/zerbaxa\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/pages\/106","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/users\/750"}],"replies":[{"embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/comments?post=106"}],"version-history":[{"count":64,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/pages\/106\/revisions"}],"predecessor-version":[{"id":2605,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/pages\/106\/revisions\/2605"}],"wp:attachment":[{"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/media?parent=106"}],"wp:term":[{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_audience?post=106"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_birn_id?post=106"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_branding?post=106"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_businessunit?post=106"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_campaign?post=106"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=106"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=106"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=106"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_experience?post=106"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_indication?post=106"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_material_intent?post=106"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_product?post=106"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_region?post=106"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=106"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/user_role?post=106"},{"taxonomy":"mhh-area-of-interest","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/mhh-area-of-interest?post=106"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/access?post=106"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/user_status?post=106"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
- \n
- The clinical significance of in vitro data is unknown<\/strong>.<\/li>\n\n\n\n
- Limitations of the SMART data include: lack of clinical information to confirm nosocomial versus community-acquired isolates, relatively small number of isolates tested each year (n=250 per site), small number of sites, and change of sites participating in SMART study over time.1<\/sup><\/li>\n\n\n\n
- Culture and susceptibility information and local epidemiology should be considered in modifying antibacterial therapy.<\/li>\n\n\n\n
- ZERBAXA is not active against bacteria that produce serine carbapenemases (K. pneumoniae<\/em> carbapenemase [KPC]), and metallo-beta-lactamases.<\/li>\n<\/ul>\n<\/div>\n\n\n\n
<\/div>\n\n\n\nSusceptibility rates for select ICU respiratory tract isolates in U.S. surveillance data (2023-2024)1,a<\/sup><\/strong><\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n<\/div>\n\n\n\n\n\n\n<\/p><\/figcaption><\/figure><\/div>\n<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\na<\/sup>Isolates were collected as part of the Study for Monitoring Antimicrobial Resistance Trends (SMART 2023-2024).1<\/sup><\/p><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\nStudy design1<\/sup><\/strong><\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\nThe Study for Monitoring Antimicrobial Resistance Trends (SMART) represents the commitment of Merck to monitor the in vitro susceptibility of clinical bacterial Gram-negative isolates to antimicrobials in intra-abdominal (since 2002), urinary tract (since 2009), respiratory tract (since 2015), and bloodstream infections (since 2019). SMART was initiated in 2002 and is a global study. This report specifically focuses on isolates from respiratory tract infections (RTIs), collected from 2023 and 2024.<\/p>\n\n\n\n
<\/div>\n\n\n\nMinimum inhibitory concentration (MIC) values for ceftolozane\/tazobactam and comparator agents were determined using the broth microdilution methodology recommended by the Clinical and Laboratory Standards Institute (CLSI) that was current in the year the data was collected. The following breakpoints were used to test for the susceptibility of P. aeruginosa<\/em> for ZERBAXA (MICs [mcg\/mL]): \u22644\/4 (susceptible).<\/p>\n\n\n\n
<\/div>\n\n\n\n\n- Back to top<\/a><\/em><\/li>
- Clinical efficacy against HABP\/VABP<\/a><\/em><\/li>
- Clinical efficacy against cUTI<\/a><\/em><\/li>
- Clinical efficacy against cIAIs<\/a><\/em><\/li><\/ul><\/div>\n\n\n\n
<\/div>\n\n\n\nZERBAXA: 9 years of P.aeruginosa<\/em> susceptibility data<\/strong><\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n\n- \n
- The clinical significance of in vitro data is unknown.<\/strong><\/li>\n\n\n\n
- Limitations of the SMART data include: lack of clinical information to confirm nosocomial versus community-acquired isolates, relatively small number of isolates tested each year (n=250 per site), small number of sites, and change of sites participating in SMART study over time.2<\/sup><\/li>\n\n\n\n
- Contributing centers collected consecutive Gram-negative bacilli from hospitalized patients with intra-abdominal, urinary, respiratory tract, or bloodstream infections.2<\/sup><\/li>\n\n\n\n
- Culture and susceptibility information and local epidemiology should be considered in modifying antibacterial therapy.<\/li>\n\n\n\n
- ZERBAXA is not active against bacteria that produce serine carbapenemases (K. pneumoniae<\/em> carbapenemase [KPC]), and metallo-beta-lactamases.<\/li>\n<\/ul>\n<\/div>\n\n\n\n
<\/div>\n\n\n\nSusceptibility rates for select isolates in US surveillance data (2016-2024)2,a<\/sup><\/strong><\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n<\/figure><\/div>\n\n\n\na<\/sup>Isolates were collected as part of the Study for Monitoring Antimicrobial Resistance Trends (SMART 2016-2024).2<\/sup><\/p>\n\n\n\n
<\/div>\n\n\n\nStudy design2<\/sup><\/strong><\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\nThe Study for Monitoring Antimicrobial Resistance Trends (SMART) was initiated by Merck in 2002 and represents the commitment of Merck to monitor the in vitro susceptibility of clinical aerobic and facultative Gram-negative bacterial isolates from intra-abdominal infections (IAIs) to selected antimicrobials internationally, enabling longitudinal analyses to determine if susceptibility patterns changed over time. Collection of isolates from urinary tract infections (UTIs), lower respiratory tract infections (RTIs), and bloodstream infections (BSIs) started in 2009, 2015, and 2019, respectively. Each participating site collected up to the indicated number of consecutive clinically relevant isolates of Gram-negative bacilli: 100 from patients with RTIs, 50 from IAIs, 50 from UTIs, and 50 from BSIs. <\/p>\n\n\n\n
<\/div>\n\n\n\nThe above collection of isolates represents the United States surveillance data of P. aeruginosa<\/em> susceptibility to ceftolozane\/tazobactam between 2016 and 2024. Minimum inhibitory concentration (MIC) was interpreted using current Clinical & Laboratory Standards Institute (CLSI) guidelines available in the United States. The following breakpoints were used to test for the susceptibility of P. aeruginosa<\/em> for ZERBAXA (MICs [mcg\/mL]): \u22644\/4 (susceptible).<\/p>\n\n\n\n
<\/div>\n\n\n\n- Back to top<\/a><\/em><\/li>
- Clinical efficacy against HABP\/VABP<\/a><\/em><\/li>
- Clinical efficacy against cUTI<\/a><\/em><\/li>
- Clinical efficacy against cIAIs<\/a><\/em><\/li><\/ul><\/div>\n\n\n\n
<\/div>\n\n\n\nReferences<\/strong><\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n- Data available on request from the Merck National Service Center via email at daprequests@merck.com. Please specify information package US-ZER-02083<\/span>.<\/li>
- Data available on request from the Merck National Service Center via email at daprequests@merck.com. Please specify information package US-ZER-02140<\/span>.<\/li><\/ol><\/div>\n\n\n\n
<\/div>\n","protected":false},"excerpt":{"rendered":"aIsolates were collected as part of the Study for Monitoring Antimicrobial Resistance Trends (SMART 2023-2024).1 The Study for Monitoring Antimicrobial Resistance Trends…<\/p>\n","protected":false},"author":750,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_trash_the_other_posts":false,"editor_notices":[],"footnotes":""},"ga4_page_audience":[],"ga4_page_birn_id":[],"ga4_page_branding":[267],"ga4_page_businessunit":[],"ga4_page_campaign":[],"ga4_page_content_purpose":[283],"ga4_page_customer_journey_stage":[334],"ga4_page_customer_specialty":[358],"ga4_page_experience":[],"ga4_page_indication":[],"ga4_page_material_intent":[522],"ga4_page_product":[706],"ga4_page_region":[749],"ga4_page_therapeuticarea":[],"user_role":[],"mhh-area-of-interest":[],"access":[],"user_status":[],"class_list":["post-106","page","type-page","status-publish"],"yoast_head":"\n
In Vitro Activity for ZERBAXA\u00ae (ceftolozane and tazobactam)<\/title>\n<meta name=\"description\" content=\"Review data for the in vitro activity of ZERBAXA\u00ae (ceftolozane and tazobactam).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"In Vitro Activity for ZERBAXA\u00ae (ceftolozane and tazobactam)\" \/>\n<meta property=\"og:description\" content=\"Review data for the in vitro activity of ZERBAXA\u00ae (ceftolozane and tazobactam).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/\" \/>\n<meta property=\"og:site_name\" content=\"zerbaxa\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-09T12:20:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.merckconnect.com\/zerbaxa\/wp-content\/uploads\/sites\/130\/2025\/10\/CAT_4_Isolates_BarChart_23-4_dk_RGB.svg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"In Vitro Activity for ZERBAXA\u00ae (ceftolozane and tazobactam)","description":"Review data for the in vitro activity of ZERBAXA\u00ae (ceftolozane and tazobactam).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/","og_locale":"en_US","og_type":"article","og_title":"In Vitro Activity for ZERBAXA\u00ae (ceftolozane and tazobactam)","og_description":"Review data for the in vitro activity of ZERBAXA\u00ae (ceftolozane and tazobactam).","og_url":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/","og_site_name":"zerbaxa","article_modified_time":"2026-04-09T12:20:50+00:00","og_image":[{"url":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-content\/uploads\/sites\/130\/2025\/10\/CAT_4_Isolates_BarChart_23-4_dk_RGB.svg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/","url":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/","name":"In Vitro Activity for ZERBAXA\u00ae (ceftolozane and tazobactam)","isPartOf":{"@id":"https:\/\/www.merckconnect.com\/zerbaxa\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/#primaryimage"},"image":{"@id":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/#primaryimage"},"thumbnailUrl":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-content\/uploads\/sites\/130\/2025\/10\/CAT_4_Isolates_BarChart_23-4_dk_RGB.svg","datePublished":"2023-08-29T13:14:44+00:00","dateModified":"2026-04-09T12:20:50+00:00","description":"Review data for the in vitro activity of ZERBAXA\u00ae (ceftolozane and tazobactam).","breadcrumb":{"@id":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/www.merckconnect.com\/zerbaxa\/invitroactivity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.merckconnect.com\/zerbaxa\/"},{"@type":"ListItem","position":2,"name":"Nonclinical data"}]},{"@type":"WebSite","@id":"https:\/\/www.merckconnect.com\/zerbaxa\/#website","url":"https:\/\/www.merckconnect.com\/zerbaxa\/","name":"zerbaxa","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.merckconnect.com\/zerbaxa\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/pages\/106","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/users\/750"}],"replies":[{"embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/comments?post=106"}],"version-history":[{"count":64,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/pages\/106\/revisions"}],"predecessor-version":[{"id":2605,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/pages\/106\/revisions\/2605"}],"wp:attachment":[{"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/media?parent=106"}],"wp:term":[{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_audience?post=106"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_birn_id?post=106"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_branding?post=106"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_businessunit?post=106"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_campaign?post=106"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=106"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=106"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=106"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_experience?post=106"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_indication?post=106"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_material_intent?post=106"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_product?post=106"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_region?post=106"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=106"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/user_role?post=106"},{"taxonomy":"mhh-area-of-interest","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/mhh-area-of-interest?post=106"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/access?post=106"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/user_status?post=106"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} - Data available on request from the Merck National Service Center via email at daprequests@merck.com. Please specify information package US-ZER-02140<\/span>.<\/li><\/ol><\/div>\n\n\n\n
- Clinical efficacy against HABP\/VABP<\/a><\/em><\/li>
- Limitations of the SMART data include: lack of clinical information to confirm nosocomial versus community-acquired isolates, relatively small number of isolates tested each year (n=250 per site), small number of sites, and change of sites participating in SMART study over time.2<\/sup><\/li>\n\n\n\n
- Clinical efficacy against HABP\/VABP<\/a><\/em><\/li>
- Limitations of the SMART data include: lack of clinical information to confirm nosocomial versus community-acquired isolates, relatively small number of isolates tested each year (n=250 per site), small number of sites, and change of sites participating in SMART study over time.1<\/sup><\/li>\n\n\n\n